



Gini F Fleming

Contact

Gini F Fleming

Publications (6)

Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown L, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller-Hübenthal B, Jochum W, Bonnefoi H, Martino S, Davidson N, Geyer C, Chia S, Ingle J, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming G, Francis P, Speed T, Regan M, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. *Ann Oncol* 2023; 34:397-409.

Francis P, Pavesi L, Ruhstaller T, Davidson N, Coleman R, Debled M, Buchholz S, Ingle J, Winer E, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates A, Gelber R, Goldhirsch A, Regan M, Climent M, Spazzapan S, Puglisi F, Pagani O, Fleming G, Walley B, Colleoni M, Láng I, Gomez H, Tondini C, Ciruelos E, Burstein H, Bonnefoi H, Bellet M, Martino S, Geyer C, Goetz M, Stearns V, Pinotti G, SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med* 2018; 379:122-137.

Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. *J Clin Oncol* 2016; 34:1601-10.

Regan M, Sessa F, Peg Cámara V, Rodríguez Peralto J, MacGrogan G, Colleoni M, Goldhirsch A, Price K, Coates A, Gelber R, Viale G, Öhlschlegel C, Pizzolitto S, Pagani O, Francis P, Fleming G, Walley B, Kammler R, Dell'Orto P, Russo L, Szóke J, Doimi F, Villani L, SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Res Treat* 2015

Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. *Lancet Oncol* 2015; 16:848-58.

Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2014; 371:107-18.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch